UHDB NHS FOUNDATION TRUST DRUG MONOGRAPH FOR USE ON CORONARY CARE UNIT

Flecainide

Indication	Atrial and ventricular tachycardias; AF cardioversion			
	See additional information for renal / hepatic / drug interaction doses.			
Dose	Loading dose 2mg/kg (actual body weight) up to maximum 150mg			
	Maintenance Infusion (Not always required) 1.5mg/kg over 1 hour then 0.1-0.25mg/kg/hour thereafter			
	Maximum dose in the first 24 hours is 600mg - infusion not generally continued after 24 hours			
	Flecainide ampoules contain 150mg in 15ml (10mg/ml)			
	Loading dose			
	1. Draw up required dose. 2. Add to 100ml bag of glucose 5%*			
Preparation				
	Maintenance Infusion Dilute to convenient volume, suggested dilution is 1mg in 1ml.			
	*Flecainide may be prepared in sodium chloride 0.9%, however, a minimum of 500ml must be used to avoid precipitation.			
	Loading dose Should be given over at least 10 minutes. In practice it is			
Administration	routinely given over 30 minutes.			
	Maintenance infusion Continuous as above			
Shelf-life	24hours at room temperature			
	Doses of flecainide should be halved in patients with CrCl <35ml/min and patients receiving amiodarone. Avoid or reduce dose in severe liver disease.			
Additional information	Digoxin levels may be increased by 15% for digitalised patients, consider checking digoxin plasma level 6hrs post digoxin dose.			
	Cardiac monitoring is advised during flecainide therapy.			
	In usual practice only the loading dose is required to cardiovert AF to sinus rhythm.			
	DRUGS ADDED TO THIS INFUSION			
Sample Label	PATIENT A. Patient (A. Number)		WARD CCU	
	DRUG Flecaíníde in 100mL Glucose 5%	AMOUNT 150mg	ADD BY	CHECKED BY
	DATE ADDED TIME ADDED	EXP. DATE EXP. TIME		BATCH No.
	DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS			

Written by Dominic Moore (Advanced Pharmacist –Specialist Medicine) August 2016 Reviewed by Hester Smail (Advanced Pharmacist - Cardiology) November 2023 Approved by Dr Damian Kelly – Lead Cardiologist Medical Division - 18/5/18

For review November 2026

References

Summary of Product Characteristics. Tambocor 10mg/ml <u>c2e4946a-45a8-4a3e-a089-</u> <u>72756ba6d63a.pdf (hpra.ie)</u> Accessed October 2023 Injectable Drugs Guide <u>https://www.new.medicinescomplete.com/#/content/idg/f04-</u> <u>mn0001?hspl=flecain</u> Accessed October 2023 Brayfield A (ed), Martindale: The Complete Drug Reference. [online] London: Pharmaceutical Press <http://www.medicinescomplete.com/> (accessed November 2023).